Show simple item record

dc.contributor.authorLiu, Xinxue
dc.contributor.authorMunro, Alasdair PS
dc.contributor.authorFeng, Shuo
dc.contributor.authorJanani, Leila
dc.contributor.authorAley, Parvinder K
dc.contributor.authorBabbage, Gavin
dc.contributor.authorBaxter, David
dc.contributor.authorBula, Marcin
dc.contributor.authorCathie, Katrina
dc.contributor.authorChatterjee, Krishna
dc.contributor.authorDejnirattisai, Wanwisa
dc.contributor.authorDodd, Kate
dc.contributor.authorEnever, Yvanne
dc.contributor.authorQureshi, Ehsaan
dc.contributor.authorGoodman, Anna L
dc.contributor.authorGreen, Christopher A
dc.contributor.authorHarndahl, Linda
dc.contributor.authorHaughney, John
dc.contributor.authorHicks, Alexander
dc.contributor.authorvan der Klaauw, Agatha A
dc.contributor.authorKwok, Jonathan
dc.contributor.authorLibri, Vincenzo
dc.contributor.authorLlewelyn, Martin J
dc.contributor.authorMcGregor, Alastair C
dc.contributor.authorMinassian, Angela M
dc.contributor.authorMoore, Patrick
dc.contributor.authorMughal, Mehmood
dc.contributor.authorMujadidi, Yama F
dc.contributor.authorHolliday, Kyra
dc.contributor.authorOsanlou, Orod
dc.contributor.authorOsanlou, Rostam
dc.contributor.authorOwens, Daniel R
dc.contributor.authorPacurar, Mihaela
dc.contributor.authorPalfreeman, Adrian
dc.contributor.authorPan, Daniel
dc.contributor.authorRampling, Tommy
dc.contributor.authorRegan, Karen
dc.contributor.authorSaich, Stephen
dc.contributor.authorSerafimova, Teona
dc.contributor.authorSaralaya, Dinesh
dc.contributor.authorScreaton, Gavin R
dc.contributor.authorSharma, Sunil
dc.contributor.authorSheridan, Ray
dc.contributor.authorSturdy, Ann
dc.contributor.authorSupasa, Piyada
dc.contributor.authorThomson, Emma C
dc.contributor.authorTodd, Shirley
dc.contributor.authorTwelves, Chris
dc.contributor.authorRead, Robert C
dc.contributor.authorCharlton, Sue
dc.contributor.authorHallis, Bassam
dc.contributor.authorRamsay, Mary
dc.contributor.authorAndrews, Nick
dc.contributor.authorLambe, Teresa
dc.contributor.authorNguyen-Van-Tam, Jonathan S
dc.contributor.authorCornelius, Victoria
dc.contributor.authorSnape, Matthew D
dc.contributor.authorFaust, Saul N
dc.contributor.authorCOV-BOOST study group
dc.date.accessioned2022-05-14T01:06:03Z
dc.date.available2022-05-14T01:06:03Z
dc.date.issued2022-06
dc.identifier.issn0163-4453
dc.identifier.other35405168
dc.identifier.otherPMC8993491
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/337153
dc.description.abstractOBJECTIVES: To evaluate the persistence of immunogenicity three months after third dose boosters. METHODS: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a third booster dose. The analysis was conducted using all randomised participants who were SARS-CoV-2 naïve during the study. RESULTS: Amongst the 2883 participants randomised, there were 2422 SARS-CoV-2 naïve participants until D84 visit included in the analysis with median age of 70 (IQR: 30-94) years. In the participants who had two initial doses of ChAdOx1 nCov-19 (Oxford-AstraZeneca; hereafter referred to as ChAd), schedules using mRNA vaccines as third dose have the highest anti-spike IgG at D84 (e.g. geometric mean concentration of 8674 ELU/ml (95% CI: 7461-10,085) following ChAd/ChAd/BNT162b2 (Pfizer-BioNtech, hearafter referred to as BNT)). However, in people who had two initial doses of BNT there was no significant difference at D84 in people given ChAd versus BNT (geometric mean ratio (GMR) of 0.95 (95%CI: 0.78, 1.15). Also, people given Ad26.COV2.S (Janssen; hereafter referred to as Ad26) as a third dose had significantly higher anti-spike IgG at D84 than BNT (GMR of 1.20, 95%CI: 1.01,1.43). Responses at D84 between people who received BNT (15 μg) or BNT (30 μg) after ChAd/ChAd or BNT/BNT were similar, with anti-spike IgG GMRs of half-BNT (15 μg) versus BNT (30 μg) ranging between 0.74-0.86. The decay rate of cellular responses were similar between all the vaccine schedules and doses. CONCLUSIONS: 84 days after a third dose of COVID-19 vaccine the decay rates of humoral response were different between vaccines. Adenoviral vector vaccine anti-spike IgG concentrations at D84 following BNT/BNT initial doses were similar to or even higher than for a three dose (BNT/BNT/BNT) schedule. Half dose BNT immune responses were similar to full dose responses. While high antibody tires are desirable in situations of high transmission of new variants of concern, the maintenance of immune responses that confer long-lasting protection against severe disease or death is also of critical importance. Policymakers may also consider adenoviral vector, fractional dose of mRNA, or other non-mRNA vaccines as third doses.
dc.languageeng
dc.publisherElsevier BV
dc.sourcenlmid: 7908424
dc.sourceessn: 1532-2742
dc.titlePersistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
dc.typeArticle
dc.date.updated2022-05-14T01:06:02Z
prism.publicationNameJ Infect
dc.identifier.doi10.17863/CAM.84572
dcterms.dateAccepted2022-04-05
rioxxterms.versionofrecord10.1016/j.jinf.2022.04.018
rioxxterms.versionVoR
dc.contributor.orcidChatterjee, Krishna [0000-0002-2654-8854]
dc.identifier.eissn1532-2742
pubs.funder-project-idWellcome Trust (210755/Z/18/Z)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record